Literature DB >> 16141603

The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes.

Motohiro Kato1, Koji Chiba, Masato Horikawa, Yuichi Sugiyama.   

Abstract

There have been no reports of the quantitative prediction of induction for drug-metabolizing enzymes in humans. We have tried to predict such enzyme induction in humans from in vitro data obtained using human hepatocytes. The in vitro and in vivo data on enzyme induction by inducers, such as rifampicin, phenobarbital and omeprazole, were collected from the published literature. The degree of enzyme induction in humans was compared with that predicted from in vitro data on human hepatocytes. Using the in vivo data, we calculated the hepatic intrinsic clearance of typical CYP substrates, such as midazolam and caffeine, before and after inducer treatment and estimated the induction ratios of hepatic intrinsic clearance following treatment. In the in vitro studies, the amount of mRNA or enzyme and enzyme activity in human hepatocytes, with or without an inducer, were compared and the induction ratios were estimated. The unbound mean concentration was taken as an index of drug exposure and the induction ratios in the in vivo and in vitro studies were compared. The unbound mean concentrations of inducers used in the in vitro studies were higher than those in the in vivo studies. The maximum induction ratios by inducers in the in vitro studies were higher than those in the in vivo studies. The induction ratio for rifampicin, omeprazole, troglitazone, dexamethasone and phenobarbital increased as the unbound mean concentration increased to reach a constant value. The induction of CYP3A and 1A was analyzed by the Emax model. The maximum induction ratio (Emax) and the concentration at half maximum induction (EC50) for rifampicin, omeprazole, troglitazone, dexamethasone and phenobarbital were 12.3, 0.847 micromol/L, 2.36, 0.225 micromol/L, 6.86, 0.002 micromol/L, 8.30, 9.32 micromol/L, and 7.62, 58.4 micromol/L, respectively. The Emax and EC50 of omeprazole for CYP1A were 12.02 and 0.075 micromol/L, respectively. The predicted induction ratio of all those inducers, except for omeprazole, based on the Emax and EC50 values obtained from the in vitro data were similar to the observed values. On the whole, a good correlation between the observed and predicted induction ratio of omeprazole was observed (r=0.768, p<0.05), although the predicted induction ratio was higher than the observed value. In conclusion, the present study suggests that it is possible to predict quantitatively the CYP3A enzyme induction from hepatocyte data.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141603     DOI: 10.2133/dmpk.20.236

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  13 in total

1.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

2.  Potential herb-drug interaction of shexiang baoxin pill in vitro based on drug metabolism/transporter.

Authors:  Zhijie Shen; Yingjie Wang; Wei Guo; Yili Yao; Xiaolong Wang
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

Review 3.  Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

4.  The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.

Authors:  Nuala A Helsby; Chung-Yee Hui; Michael A Goldthorpe; Janet K Coller; May Ching Soh; Peter J Gow; Janak Z De Zoysa; Malcolm D Tingle
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

5.  A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

Authors:  Steven N Hart; Ye Li; Kaori Nakamoto; Eva-anne Subileau; David Steen; Xiao-bo Zhong
Journal:  Drug Metab Dispos       Date:  2010-03-12       Impact factor: 3.922

6.  General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.

Authors:  Yoshiyuki Ohno; Akihiro Hisaka; Masaki Ueno; Hiroshi Suzuki
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin.

Authors:  Min-Ho Park; Seok-Ho Shin; Jin-Ju Byeon; Gwan-Ho Lee; Byung-Yong Yu; Young G Shin
Journal:  Korean J Physiol Pharmacol       Date:  2016-12-21       Impact factor: 2.016

8.  Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.

Authors:  Ryuta Asaumi; Kota Toshimoto; Yoshifusa Tobe; Kenta Hashizume; Ken-Ichi Nunoya; Haruo Imawaka; Wooin Lee; Yuichi Sugiyama
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-02-05

9.  Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data.

Authors:  Fumiyoshi Yamashita; Yukako Sasa; Shuya Yoshida; Akihiro Hisaka; Yoshiyuki Asai; Hiroaki Kitano; Mitsuru Hashida; Hiroshi Suzuki
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

10.  Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.

Authors:  Eric A Benson; Michael T Eadon; Zeruesenay Desta; Yunlong Liu; Hai Lin; Kimberly S Burgess; Matthew W Segar; Andrea Gaedigk; Todd C Skaar
Journal:  Front Pharmacol       Date:  2016-04-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.